CSPI says FDA peptide decisions leave consumers exposed to harm
The consumer advocacy group is publicly criticizing the agency's handling of peptide products rather than the products' manufacturers.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 26 12:02 ETSource: Center for Science in the Public Interest
The wire
- 01The Center for Science in the Public Interest published a piece arguing that recent FDA moves on peptides put consumers in harm's way.
- 02Clinicians, compounders and telehealth operators track CSPI commentary because it often precedes congressional or agency scrutiny of product categories.
- 03Details of which specific agency actions are faulted, and any FDA response, are not laid out in the item itself.
From the source
Read at cspi.orgFDA moves on peptides put consumers in harm's way
